SER-AP-ES
LOE ApproachingNDAORALTABLET
Approved
Feb 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SER-AP-ES is an oral small-molecule tablet approved by Novartis in 1960 with an unknown mechanism of action and indication profile. The drug's mechanism, pharmacologic class, and therapeutic indications are not publicly documented in available data.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals contraction; team likely focused on generic transition strategy rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SER-AP-ES offers limited career growth exposure given zero linked job postings and approaching LOE status. Roles focus on legacy management, cost containment, and competitive defense rather than market expansion or innovation.
Brand ManagerField Sales Representative
Worked on SER-AP-ES at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.